Other: Fluid Restriction ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
72	下垂体性ADH分泌異常症	1

72. 下垂体性ADH分泌異常症

---

臨床試験数 : 40 /  薬物数 : 28 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 9

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01227512 (ClinicalTrials.gov)	October 2010	22/10/2010	Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia	Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia	Hyponatremia;Dilutional Hyponatremia;Inappropriate ADH Syndrome	Drug: tolvaptan;Other: Fluid Restriction	Otsuka Pharmaceutical Development & Commercialization, Inc.	NULL	Terminated	18 Years	N/A	All	124	Phase 3	United States